Skip to content

A clinical trial to study the effects of a drug named Brahma Rasayan in Patients with Manasamanadata (Mental Retardation)

Clinical Evaluation of Brahma Rasayana in the Management of ââ?¬Å?Manasamandata (Mental Retardation)ââ?¬? ââ?¬â?? an open clinical trial. - Manasa Mandata (MR)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/05/005799
Enrollment
90
Registered
2015-05-22
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G431- Migraine with aura Health Condition 2: G430- Migraine without aura

Interventions

Intervention1: Brahma Rasayana: Dose :6gm twice daily, Dosage form:Lehyam, Route of Administration:Oral, Time of Administration:7.30 am before breakfast&7.30pm before dinner, Anupana:Potable Water, Qu

Sponsors

Central Council For Research In Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Children of either sex aged in between 6 to 13 years. 2.Children who meet ICD-10 criteria for mild mental retardation. 3.Willing and able to participate for 6 months (consent to be obtained from Parent(s) / Guardian(s)). 4.Assent from children wherever possible.

Exclusion criteria

Exclusion criteria: 1.Children with a history of peptic ulcer disease, any gastric or duodenal surgery, gastrointestinal (GI) bleeding or other GI disorders. 2.Children with severe infection and/or clinically significant hepatic, respiratory, renal, cardiac or hematological disorders. 3.Children with abnormal laboratory values at admission in to the study: serum creatinine 1.2 > mg/dl, SGOT, SGPT >3times upper limit of normal; serum Bilirubin or Alkaline phosphatase >1.5 times upper limit of normal. 4.Patientââ?¬•s guardian who cannot be relied upon to comply with the test procedures or are unwilling to give informed consent. 5.The Children had any intramuscular, intra-articular or intravenous corticosteroids within 4 weeks prior to study entry. 6.The Children with a history of recent and clinically significant drug abuse. 7.The Children with pre-existing blood dyscrasias, eg., bone marrow hypoplasia, leukopenia, thrombocytopenia etc. 8.The Children is unlikely to comply with protocol, eg., un cooperative attitude, inability to return for follow-up visits, and unlikelihood of complete study. 9.Children in whom another investigational drug was used with in 3 months prior to entry in this study. 10.Children with poorly controlled epilepsy (H/o attack in last 3 months). 11.Children to whom BKT / VSMS canââ?¬•t be administered for any reason

Design outcomes

Primary

MeasureTime frame
Changes in BKT or VSMS Abnormal behavioral test and Parental Perception EvaluationTimepoint: BKT or VSMS at Base Line, at the end of 3 months and at the end of 6 months ABT at Base line, at the end of 1,2 ,3 ,4 ,5 and 6months Parental perception at the end of 6 months

Secondary

MeasureTime frame
Symptomatic ImprovementTimepoint: At the end of 1,2,3,4,5 and 6 months

Countries

India

Contacts

Public ContactDr D Sudhakar

Central Council for Research in Ayurvedic Sciences

acamhns.bengaluru@gmail.com08026995243

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 5, 2026